Combining the FAK/Pyk2 inhibitor PF-56227 with temozolomide (TMZ) can enhance the effectiveness of TMZ in inhibiting tumour growth and spread, ultimately improving treatment outcomes (Ortiz-Rivera et al., 2023). The gene discussed is PTK2; the disease is neoplasm.